- Home
- SLAI vs LEXX Comparison
SLAI vs LEXX Comparison
Compare SLAI & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLAI
- LEXX
- Stock Information
- Founded
- SLAI 2001
- LEXX 2004
- Country
- SLAI United States
- LEXX Canada
- Employees
- SLAI N/A
- LEXX N/A
- Industry
- SLAI EDP Services
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- SLAI Technology
- LEXX Health Care
- Exchange
- SLAI Nasdaq
- LEXX Nasdaq
- Market Cap
- SLAI 23.1M
- LEXX 23.9M
- IPO Year
- SLAI N/A
- LEXX N/A
- Fundamental
- Price
- SLAI $2.38
- LEXX $1.00
- Analyst Decision
- SLAI
- LEXX Strong Buy
- Analyst Count
- SLAI 0
- LEXX 1
- Target Price
- SLAI N/A
- LEXX $4.00
- AVG Volume (30 Days)
- SLAI 390.9K
- LEXX 373.7K
- Earning Date
- SLAI 11-19-2025
- LEXX 11-25-2025
- Dividend Yield
- SLAI N/A
- LEXX N/A
- EPS Growth
- SLAI N/A
- LEXX N/A
- EPS
- SLAI N/A
- LEXX N/A
- Revenue
- SLAI $24,576,000.00
- LEXX $615,923.00
- Revenue This Year
- SLAI N/A
- LEXX $46.98
- Revenue Next Year
- SLAI N/A
- LEXX $17.26
- P/E Ratio
- SLAI N/A
- LEXX N/A
- Revenue Growth
- SLAI N/A
- LEXX 49.85
- 52 Week Low
- SLAI $1.22
- LEXX $0.77
- 52 Week High
- SLAI $8.07
- LEXX $2.85
- Technical
- Relative Strength Index (RSI)
- SLAI N/A
- LEXX 54.16
- Support Level
- SLAI N/A
- LEXX $0.80
- Resistance Level
- SLAI N/A
- LEXX $0.96
- Average True Range (ATR)
- SLAI 0.00
- LEXX 0.07
- MACD
- SLAI 0.00
- LEXX 0.01
- Stochastic Oscillator
- SLAI 0.00
- LEXX 74.05
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.